Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492226 | 0.84 | ADRB1 (0.51) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL23619249 | 0.80 | POLB (0.37) | ADRB1DNMT1TK2 | |
| SCHEMBL22577616 | 0.78 | MAPT (0.57) | DNMT1LMNASMN1; SMN2 | |
| SCHEMBL22080061 | 0.78 | ABL1 (0.45) | LMNAPIM1 | |
| SCHEMBL25813255 | 0.78 | ABL1 (0.45) | LMNAPIM1 | |
| SCHEMBL22992579 | 0.78 | TK1 (0.48) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL4810094 | 0.78 | TK1 (0.51) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL24420515 | 0.78 | TK1 (0.48) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL24420755 | 0.78 | TK1 (0.48) | ADRB1DNMT1LMNASMN1; SMN2TK1 | |
| SCHEMBL16348682 | 0.78 | TK1 (0.48) | ADRB1DNMT1LMNASMN1; SMN2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADRB1 583/4885DNMT1 2668/4885LMNA 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.